Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 8/20 | 1.00 |
| ▸ | PTPRC | P08575 | 1/20 | 0.67 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405870 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPN5 | |
| SCHEMBL2690335 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPN5 | |
| SCHEMBL3746043 | 0.81 | PTPN1 (0.72) | PTPN1PTPN2PTPRC | |
| SCHEMBL30163144 | 0.81 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL2691286 | 0.81 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL2694340 | 0.80 | PTPN1 (0.67) | PTPN1PTPN2PTPRC | |
| SCHEMBL2690504 | 0.80 | PTPN1 (0.67) | PTPN1PTPN2PTPRC | |
| SCHEMBL4410196 | 0.79 | PTPN1 (0.67) | PTPN1PTPN2PTPRC | |
| SCHEMBL2691376 | 0.79 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL16525900 | 0.78 | PTPN1 (0.63) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2013155600-A1 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS | KANEQ PHARMA (CA) | 2013-10-24 | — | — | WO | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | KANEQ PHARMA INC. (CA) | 2012-07-12 | — | — | US | disclosed |
| US-8168815-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20120014911-A1 | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2012-01-19 | — | — | US | disclosed |
| WO-2010080992-A1 | REGULATORS OF THE INTERFERON-ALPHA RECEPTOR 1 (IFNAR1) CHAIN OF THE INTERFERON RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2010-01-28 | — | — | US | disclosed |
| EP-2114971-A1 | FUSED AROMATIC PTP-1B INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089581-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | PTPN1 3362/4885PTPN2 3181/4885PTPRC 1607/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | PTPN1 2492/4885PTPN2 2059/4885PTPRC 2060/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | PTPN1 1281/4885PTPN2 1598/4885PTPRC 335/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | PTPN1 1521/4885PTPN2 1356/4885PTPRC 2773/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | PTPN1 1382/4885PTPN2 1848/4885PTPRC 906/4885 |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | PTPRF, PTPRJ, PTPRCAP | PTPN1 15/4885PTPN2 23/4885PTPRC 7/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | PTPN1 1137/4885PTPN2 1382/4885PTPRC 258/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | PTPN1 3362/4885PTPN2 3181/4885PTPRC 1607/4885 |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | PTPN1 14/4885PTPN2 22/4885PTPRC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.